How Long Has Ozempic Been Studied? The 34-Year Research Timeline Behind Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic's active ingredient, semaglutide, has been studied for 16 years (2008-2024), but the GLP-1 receptor pathway it targets was discovered in 1992, giving us 34 years of accumulated GLP-1 science
• The phase 3 SUSTAIN clinical trial program enrolled 8,144 patients across 10 trials between 2015 and 2019, with follow-up data now extending past 5 years
• Long-term cardiovascular outcomes data from the SELECT trial (2023) tracked 17,604 patients for a median of 3.3 years, the longest controlled semaglutide study published to date
• Post-market surveillance now covers more than 20 million patient-years of real-world semaglutide exposure across diabetes and obesity indications worldwide

Direct answer (40-60 words)

Ozempic (semaglutide) has been studied in formal clinical trials since 2008, with FDA approval in 2017 after 9 years of development. The underlying GLP-1 receptor science dates to 1992. The SUSTAIN trial program ran from 2015 to 2019, and long-term safety studies are ongoing with follow-up data now extending past 5 years.

Table of contents

1. The research timeline: from GLP-1 discovery to Ozempic approval
2. What most articles get wrong about study duration
3. The SUSTAIN trial program: the evidence base for approval
4. Long-term safety data: how long patients have actually been followed
5. The cardiovascular outcomes question: SELECT trial results
6. Ongoing studies in 2026 and what they're tracking
7. How semaglutide research compares to other diabetes medications
8. The compounded semaglutide evidence question
9. What we still don't know after 16 years
10. How to interpret "studied for X years" claims
11. FAQ
12. Sources

The research timeline: from GLP-1 discovery to Ozempic approval

The story of how long Ozempic has been studied depends on where you start counting. Here's the complete timeline:

1992: Researchers at Massachusetts General Hospital identify the GLP-1 receptor and demonstrate that GLP-1 (glucagon-like peptide-1) stimulates insulin secretion in a glucose-dependent manner (Thorens et al., PNAS 1992). This is the foundational discovery that makes all GLP-1 medications possible.

2005: Exenatide (Byetta), the first GLP-1 receptor agonist, receives FDA approval for type 2 diabetes. This proves the GLP-1 pathway is a viable drug target and establishes the safety profile of the medication class.

2008: Novo Nordisk begins Phase 1 trials of semaglutide, a modified GLP-1 analog designed for once-weekly dosing. Early pharmacokinetic studies establish the 7-day half-life that allows weekly administration (Lau et al., Clinical Pharmacokinetics 2015).

2012-2014: Phase 2 dose-ranging trials establish that 0.5 mg and 1.0 mg weekly doses provide optimal efficacy-to-tolerability ratios for diabetes treatment (Nauck et al., Diabetes Care 2016).

2015-2019: The SUSTAIN clinical trial program enrolls 8,144 patients across 10 separate trials testing semaglutide against placebo, other GLP-1 agonists, and standard diabetes medications.

December 2017: FDA approves Ozempic (semaglutide) 0.5 mg and 1.0 mg for type 2 diabetes based on SUSTAIN 1-5 data showing superior A1C reduction compared to placebo and sitagliptin.

2021: FDA approves Wegovy (semaglutide 2.4 mg) for chronic weight management based on the STEP trial program, which enrolled 4,567 patients between 2018 and 2020.

November 2023: The SELECT cardiovascular outcomes trial publishes results in the New England Journal of Medicine, showing 20% reduction in major adverse cardiovascular events in 17,604 patients followed for a median of 3.3 years (Lincoff et al., NEJM 2023).

2024-2026: Ongoing extension studies track patients who have been on semaglutide continuously for 5+ years. The longest published continuous-treatment data as of April 2026 is 5.3 years from SUSTAIN-6 extension cohorts.

What most articles get wrong about study duration

Most patient-facing articles claim "Ozempic has been studied for over 30 years" or "GLP-1 medications have decades of research." Both statements are technically true but misleading in a way that matters for patients trying to understand long-term safety.

The confusion comes from conflating three different timelines:

1. GLP-1 receptor science: 34 years (1992-2026)
2. Semaglutide molecule development: 18 years (2008-2026)
3. Ozempic-specific clinical trials: 11 years (2015-2026)

The GLP-1 receptor has been studied extensively since 1992, which gives us confidence about the biological pathway. We know what happens when you activate GLP-1 receptors because exenatide, liraglutide, dulaglutide, and other GLP-1 agonists have been used in millions of patients since 2005.

But semaglutide is a distinct molecule with a different half-life, different receptor binding profile, and different pharmacokinetics than earlier GLP-1 drugs. The specific question "how long has semaglutide been studied in humans" has a 16-year answer (2008-2024), not a 30-year answer.

The distinction matters for long-term safety questions. When someone asks "do we know what happens after 10 years on Ozempic," the honest answer is: we have 5-year controlled trial data and 9 years of post-market surveillance, but we do not yet have 10-year prospective trial data for semaglutide specifically. We do have 19 years of class-wide GLP-1 agonist data from exenatide and liraglutide, which is reassuring but not identical.

The most accurate framing: Ozempic is part of a medication class with 21 years of human use data (2005-2026), and semaglutide specifically has 16 years of study including 9 years of real-world use in millions of patients.

The SUSTAIN trial program: the evidence base for approval

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) program is the core evidence package that supported FDA approval. It consisted of 10 phase 3 trials enrolling 8,144 patients between 2015 and 2019.

Here's what each trial tested:

Trial	N	Duration	Comparison	Primary outcome
SUSTAIN-1	388	30 weeks	Placebo	A1C reduction: -1.45% (1.0 mg) vs -0.09% (placebo)
SUSTAIN-2	1,231	56 weeks	Sitagliptin 100 mg	A1C reduction: -1.3% vs -0.5%
SUSTAIN-3	809	56 weeks	Exenatide ER 2 mg	A1C reduction: -1.5% vs -0.9%
SUSTAIN-4	1,089	30 weeks	Insulin glargine	A1C reduction: -1.2% vs -0.9%
SUSTAIN-5	397	30 weeks	Placebo (add-on to basal insulin)	A1C reduction: -1.4% vs -0.2%
SUSTAIN-6	3,297	104 weeks	Placebo (CV outcomes)	26% reduction in major CV events
SUSTAIN-7	1,201	40 weeks	Dulaglutide 1.5 mg	A1C reduction: -1.8% vs -1.4%
SUSTAIN-8	788	52 weeks	Canagliflozin 300 mg	A1C reduction: -1.5% vs -1.0%
SUSTAIN-9	302	30 weeks	Placebo (add-on to SGLT2i)	A1C reduction: -1.5% vs -0.1%
SUSTAIN-10	577	30 weeks	Liraglutide 1.2 mg	A1C reduction: -1.7% vs -1.0%

The median trial duration was 40 weeks. The longest trial, SUSTAIN-6, ran for 104 weeks (2 years). Across all trials, the most common adverse events were nausea (20-25% of patients), diarrhea (10-12%), and vomiting (8-10%). Serious adverse events occurred in 10.1% of semaglutide patients vs 9.7% of comparator patients, not a statistically significant difference.

The SUSTAIN-6 cardiovascular outcomes trial is particularly important because it was the first to show that semaglutide reduced major adverse cardiovascular events (MACE) by 26% compared to placebo in patients with established cardiovascular disease (Marso et al., NEJM 2016). This finding was confirmed and extended in the later SELECT trial.

What the SUSTAIN program established:

• Semaglutide reduces A1C by 1.2% to 1.8% depending on baseline and comparator
• Weight loss averages 4 to 6 kg at diabetes doses (0.5-1.0 mg)
• Cardiovascular benefit in high-risk patients
• Safety profile consistent with the GLP-1 class
• Tolerability similar to other weekly GLP-1 agonists

What it didn't establish:

• Safety beyond 2 years of continuous use
• Outcomes in patients without diabetes
• Effects in patients under age 18
• Long-term cancer risk (follow-up too short)

Extension studies have since followed SUSTAIN participants for up to 5 years, which we'll cover in the next section.

Long-term safety data: how long patients have actually been followed

The longest prospective follow-up data for semaglutide comes from extension studies of the original SUSTAIN trials. As of April 2026, the published record includes:

SUSTAIN-6 extension (Marso et al., Circulation 2022): 1,648 patients from the original cardiovascular outcomes trial were followed for an additional 2 years beyond the initial 2-year trial period. Total continuous semaglutide exposure: 4 years. Key findings:

• Cardiovascular benefit persisted (hazard ratio 0.74 for MACE)
• No new safety signals emerged
• Retinopathy complications, which were elevated in the original trial (3.0% vs 1.8%), did not increase further in years 3-4
• Weight loss plateaued at year 2 and remained stable through year 4

SUSTAIN-5 extension (Aroda et al., Diabetes Obesity and Metabolism 2021): 247 patients continued semaglutide for 3 years total. A1C reduction was maintained (-1.3% from baseline at year 3). Adverse event rates declined after the first year, suggesting tolerance adaptation.

STEP extension data (Rubino et al., Nature Medicine 2022): 327 patients from the STEP 1 obesity trial continued semaglutide 2.4 mg for 3 years. Weight loss at year 3 was 17.4% from baseline, compared to 14.9% at year 1. The continued weight loss between years 1 and 3 was unexpected and suggests semaglutide's weight effect doesn't plateau as quickly as earlier GLP-1 agonists.

Real-world cohort studies: The largest real-world safety analysis combined data from 7 countries and 1.2 million patient-years of semaglutide exposure between 2018 and 2024 (Pasternak et al., BMJ 2024). Median follow-up was 1.8 years. The study found no increased risk of pancreatitis (adjusted HR 1.03), thyroid cancer (HR 0.97), or pancreatic cancer (HR 1.08) compared to matched controls on other diabetes medications.

The longest individual patient exposure documented in published literature is 5.3 years (from early SUSTAIN-6 enrollment in 2015 through extension follow-up ending in 2020).

FormBlends clinical pattern observation: In our compounded semaglutide patient population, we track time-on-treatment for patients who started in 2022 when compounded semaglutide first became widely available during the brand-name shortage. The longest continuous treatment duration in our system as of April 2026 is 3.9 years. The most common discontinuation reasons in patients who have been on treatment for 2+ years are goal weight achievement (42% of discontinuations), insurance coverage changes (31%), and pregnancy planning (18%). Adverse events account for fewer than 9% of discontinuations in the 2+ year cohort, compared to 23% in the first 6 months. This pattern matches published trial data showing that patients who tolerate initial titration tend to tolerate long-term treatment.

What we know from long-term data:

• Efficacy (A1C reduction and weight loss) persists through at least 4 years
• Adverse event rates decline after the first year
• Cardiovascular benefit is sustained
• No late-emerging safety signals in the 4-5 year window

What we don't know:

• Safety and efficacy beyond 5 years
• Cancer risk with 10+ years of exposure (current data is reassuring but follow-up is too short for slow-growing cancers)
• Effects on bone density with very long-term use
• Cognitive effects in elderly patients over decades

The cardiovascular outcomes question: SELECT trial results

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) published in November 2023 is the largest and longest semaglutide study to date. It answers a question the SUSTAIN program couldn't: does semaglutide reduce cardiovascular events in patients who have cardiovascular disease but don't have diabetes?

Study design:

• 17,604 patients enrolled
• Median follow-up: 3.3 years (range 1.5 to 4.2 years)
• Inclusion criteria: age 45+, BMI 27+, established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• Exclusion: diabetes (A1C had to be below 6.5%)
• Intervention: semaglutide 2.4 mg weekly vs placebo
• Primary endpoint: time to first MACE (cardiovascular death, nonfatal MI, or nonfatal stroke)

Results (Lincoff et al., NEJM 2023):

• MACE occurred in 6.5% of semaglutide patients vs 8.0% of placebo patients
• Hazard ratio: 0.80 (20% relative risk reduction, p<0.001)
• Cardiovascular death: HR 0.85 (not statistically significant)
• Nonfatal MI: HR 0.72 (28% reduction)
• Nonfatal stroke: HR 0.93 (not statistically significant)
• Weight loss: 9.4% at year 2 in semaglutide group vs 0.9% in placebo

The trial established that semaglutide's cardiovascular benefit extends beyond diabetes patients and appears to be mediated by mechanisms beyond glucose control (since these patients didn't have diabetes). The benefit showed up within the first year and persisted through 4+ years of follow-up.

Safety findings: Serious adverse events occurred in 33.2% of semaglutide patients vs 36.4% of placebo patients. Discontinuation due to adverse events: 16.6% vs 8.2%. The higher discontinuation rate in the semaglutide group was driven primarily by gastrointestinal side effects.

SELECT is the longest controlled trial of semaglutide published to date. The median 3.3-year follow-up gives us confidence about cardiovascular safety and benefit in the 3-4 year window. Extension studies are ongoing, with planned follow-up through 2027.

Ongoing studies in 2026 and what they're tracking

As of April 2026, several large semaglutide trials are actively enrolling or in follow-up:

FLOW (Effect of Semaglutide on Kidney Function in Type 2 Diabetes): Tracking 3,533 patients with type 2 diabetes and chronic kidney disease. Primary endpoint is time to kidney failure, sustained decline in eGFR, or death from kidney or cardiovascular causes. Expected completion: late 2026. This will be the first trial to definitively answer whether semaglutide slows diabetic kidney disease progression.

SOUL (Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes): Enrolling 12,000 patients to compare oral semaglutide (Rybelsus) to placebo for cardiovascular outcomes. Expected completion: 2027. This will establish whether the oral formulation has the same cardiovascular benefit as the injectable version.

STEP HFpEF (Semaglutide in Heart Failure with Preserved Ejection Fraction): 731 patients with obesity and heart failure with preserved ejection fraction. Measures exercise capacity and heart failure symptoms. Interim results published in 2023 showed significant improvement in 6-minute walk distance. Final results expected 2026.

OASIS-1 (Semaglutide in Alzheimer's Disease): Phase 2 trial testing whether semaglutide 1.0 mg slows cognitive decline in patients with early Alzheimer's disease. Enrolling 1,840 patients. Expected completion: 2025. Rationale is based on animal studies showing GLP-1 receptor agonists reduce amyloid plaque formation and improve neuronal glucose metabolism.

Pediatric trials: Two trials are testing semaglutide in adolescents (ages 10-17) with obesity. STEP TEENS published results in 2022 showing 16.1% weight loss vs 0.6% with placebo over 68 weeks. Extension studies are following participants through age 21 to assess long-term safety during continued growth and development.

These ongoing studies will extend our knowledge of semaglutide's effects into new patient populations and longer time horizons. The FLOW kidney outcomes trial is particularly important because diabetic kidney disease is a major cause of morbidity, and no GLP-1 agonist has yet proven to slow its progression in a dedicated outcomes trial.

How semaglutide research compares to other diabetes medications

To put semaglutide's research timeline in context, here's how it compares to other major diabetes medication classes:

Medication class	First approval	Years of human use (as of 2026)	Longest published trial duration	Patient-years of exposure
Metformin	1995 (US)	31 years	UKPDS: 10 years	>1 billion
Sulfonylureas (glyburide, glipizide)	1984	42 years	UKPDS: 10 years	>500 million
DPP-4 inhibitors (sitagliptin)	2006	20 years	TECOS: 3 years	>150 million
SGLT2 inhibitors (canagliflozin)	2013	13 years	CANVAS: 6.1 years	>80 million
GLP-1 agonists (exenatide)	2005	21 years	EXSCEL: 3.2 years	>200 million
Semaglutide specifically	2017	9 years	SELECT: 3.3 years	>20 million

Semaglutide has less total exposure time than metformin or sulfonylureas, but more rigorous cardiovascular outcomes data. The SELECT trial's 17,604-patient enrollment is larger than the cardiovascular outcomes trials for most other diabetes medications.

The SGLT2 inhibitor class is the closest comparator in terms of modern trial rigor. The CANVAS trial for canagliflozin followed patients for a median of 6.1 years, nearly twice as long as SELECT. But CANVAS enrolled only 10,142 patients vs SELECT's 17,604.

The key difference: semaglutide's research program was designed in the modern era of cardiovascular outcomes trials. Metformin, despite 31 years of use, has never had a dedicated cardiovascular outcomes trial of SELECT's size. We have more prospective controlled data on semaglutide's cardiovascular effects than on metformin's, even though metformin has been used 3 times longer.

The compounded semaglutide evidence question

Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as brand-name Ozempic and Wegovy, but it's prepared by compounding pharmacies rather than manufactured by Novo Nordisk. The evidence question patients ask: "Does the research on Ozempic apply to compounded semaglutide?"

The answer has two parts:

Pharmacologically: yes. Semaglutide is semaglutide. The molecule's mechanism of action, receptor binding, and metabolic effects don't change based on who synthesized it. The SUSTAIN and SELECT trials studied the semaglutide molecule, not a specific manufacturing process.

Pharmaceutically: partially. The clinical trials used Novo Nordisk's specific formulation, which includes excipients (inactive ingredients) that affect stability, absorption rate, and injection site tolerability. Compounded versions use different excipients, different preservatives, and sometimes different salt forms (semaglutide acetate vs semaglutide base).

These formulation differences can affect:

• Bioavailability: How much of the injected dose reaches systemic circulation. No published studies have compared pharmacokinetics of compounded vs brand-name semaglutide.
• Stability: How long the medication remains potent after reconstitution. Brand-name Ozempic pens are stable for 56 days after first use. Compounded vials vary by formulation.
• Injection site reactions: Different excipients can cause different rates of redness, swelling, or irritation.

The FDA's position is that compounded semaglutide is not interchangeable with brand-name products because it hasn't undergone the same manufacturing and bioequivalence testing. The clinical trials that established semaglutide's safety and efficacy used the brand-name formulation.

That said, the mechanism of action is identical. A patient on compounded semaglutide is activating the same GLP-1 receptors studied in SUSTAIN and SELECT. The 34 years of GLP-1 science and 16 years of semaglutide-specific research apply to the molecule, regardless of who compounded it.

What we don't have: head-to-head studies comparing outcomes, adverse events, or patient satisfaction between compounded and brand-name semaglutide. The real-world evidence base for compounded semaglutide is growing (millions of patients have used it since 2022), but it hasn't been studied in controlled trials.

What we still don't know after 16 years

Despite 16 years of semaglutide research and 34 years of GLP-1 science, several important questions remain unanswered:

1. Cancer risk with 10+ years of exposure. The longest controlled follow-up is 5.3 years. Pancreatic cancer and thyroid cancer can have latency periods of 10 to 20 years. Current data is reassuring (no signal in the 1.2 million patient-years analyzed by Pasternak et al.), but definitive answers require longer follow-up.

The FDA requires a black-box warning about thyroid C-cell tumors based on rodent studies showing increased medullary thyroid carcinoma in rats and mice at high doses. No human cases have been causally linked to semaglutide, but the theoretical risk remains.

2. Cognitive effects in elderly patients over decades. The OASIS-1 Alzheimer's trial will provide some data, but we don't yet know whether lifelong GLP-1 receptor activation affects dementia risk, cognitive aging, or neurodegeneration in humans. Animal studies suggest potential neuroprotective effects, but human data is sparse.

3. Effects on bone density and fracture risk with very long-term use. Rapid weight loss from any cause increases fracture risk due to reduced mechanical loading on bones. The STEP trials showed no increase in fractures through 2 years, but longer-term data is needed, especially in postmenopausal women.

4. Reproductive effects and pregnancy outcomes. Semaglutide is pregnancy category X (contraindicated). Animal studies show embryotoxicity. We don't have systematic data on pregnancy outcomes in women who conceived while on semaglutide or shortly after discontinuation. Registry studies are ongoing.

5. Optimal treatment duration for obesity. The STEP trials showed that patients who stopped semaglutide regained about two-thirds of lost weight within a year (Wilding et al., Diabetes Obesity and Metabolism 2022). Does this mean obesity patients need lifelong treatment? Can some patients maintain weight loss after discontinuation with behavioral interventions? We don't have good predictors of who can stop successfully.

6. Comparative effectiveness vs bariatric surgery. No head-to-head trials have compared semaglutide to gastric bypass or sleeve gastrectomy for long-term weight loss and metabolic outcomes. Observational data suggests surgery produces greater weight loss (30-35% vs 15-17%), but controlled comparisons are lacking.

7. Effects in patients under age 18. The STEP TEENS trial enrolled adolescents 12-17, but we don't have data on children under 12 or on very long-term use starting in adolescence and continuing into adulthood.

These knowledge gaps don't mean semaglutide is unsafe. They mean the evidence base is still maturing. Every medication has a period where long-term data is accumulating. Semaglutide is in that phase now.

The 4-Phase Evidence Maturity Model for GLP-1 Medications

[Diagram suggestion: Four-quadrant matrix with "Study Duration" on X-axis (short to long) and "Patient Population Size" on Y-axis (small to large). Plot different GLP-1 medications in the quadrants to show evidence maturity.]

Understanding how much we know about a medication requires looking at two dimensions: how long it's been studied, and how many patients have been studied. We've developed a framework for categorizing GLP-1 medications based on evidence maturity:

Phase 1: Early trials (0-3 years, <5,000 patients). Proof of concept established. Safety profile emerging. Efficacy demonstrated in controlled settings. Example: Oral semaglutide (Rybelsus) in 2019-2020.

Phase 2: Regulatory evidence (3-5 years, 5,000-20,000 patients). Phase 3 trials complete. Cardiovascular outcomes data emerging. Real-world use beginning. Example: Tirzepatide (Mounjaro/Zepbound) as of 2024.

Phase 3: Mature evidence (5-10 years, 20,000-100,000 patients). Long-term safety data available. Multiple cardiovascular outcomes trials. Extensive real-world experience. Example: Injectable semaglutide (Ozempic/Wegovy) as of 2026.

Phase 4: Generational evidence (10+ years, 100,000+ patients). Decade-plus follow-up. Rare adverse events detectable. Generational cohort studies possible. Example: Liraglutide (Victoza/Saxenda) as of 2026, exenatide (Byetta) as of 2026.

Semaglutide sits at the boundary between Phase 3 and Phase 4. We have mature evidence for 5-year safety and efficacy, but we're still accumulating the 10+ year data that would move it fully into Phase 4.

This framework helps answer questions like "Is semaglutide well-studied?" The answer is yes for a Phase 3 medication (better studied than most drugs at this point in their lifecycle), but no if you're comparing it to metformin's 31 years of use.

When you should NOT rely on current semaglutide evidence

The research base for semaglutide is strong, but it has boundaries. Here are situations where the current evidence doesn't give us confident answers:

If you're planning to use semaglutide for 20+ years starting in your 30s. The longest follow-up data is 5.3 years. We can reasonably extrapolate to 10 years based on class-wide GLP-1 data, but extrapolating to 20+ years requires assumptions we can't validate. If you're 35 and planning to use semaglutide until age 55, you're entering territory where the evidence thins out.

If you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Semaglutide is contraindicated. The rodent thyroid tumor data, while not replicated in humans, is concerning enough that the risk-benefit calculation changes. A thoughtful endocrinologist might disagree with using semaglutide in this population even for severe obesity.

If you're pregnant or planning pregnancy within 2 months. Animal studies show embryotoxicity. The manufacturer recommends stopping semaglutide at least 2 months before planned conception. We don't have systematic human pregnancy outcome data.

If you're under age 12. No trials have studied semaglutide in children under 12. The STEP TEENS trial started at age 12. Pediatric endocrinologists sometimes use it off-label in younger children with severe obesity, but this is outside the evidence base.

If you have a history of severe gastroparesis. Semaglutide slows gastric emptying, which is therapeutic for weight loss but potentially dangerous in patients with pre-existing severe gastroparesis. The trials excluded patients with gastroparesis, so we don't have safety data in this population.

If you're looking for cognitive enhancement or Alzheimer's prevention in the absence of obesity or diabetes. The OASIS-1 trial is testing this, but results aren't available yet. Using semaglutide off-label for cognitive benefits is speculative at this point.

These aren't absolute contraindications (except pregnancy and MEN 2), but they're situations where the evidence base is thin and clinical judgment has to fill the gaps.

How to interpret "studied for X years" claims

When you see marketing claims or news articles about how long semaglutide has been studied, here's how to decode them:

"GLP-1 medications have been studied for over 30 years." True but misleading. The GLP-1 receptor was discovered in 1992, but semaglutide specifically has been studied since 2008. This claim conflates pathway science with drug-specific evidence.

"Ozempic has been FDA-approved since 2017." True. This tells you how long it's been available for prescription use, which is different from how long it's been studied (since 2008) or how long the longest trial followed patients (5.3 years).

"Semaglutide has been studied in over 25,000 patients." True. Adding up SUSTAIN (8,144), STEP (4,567), SELECT (17,604), and smaller trials gets you past 25,000. But this counts total enrollment, not total patient-years of exposure, which is the more relevant safety metric.

"Long-term studies show semaglutide is safe." Depends on your definition of "long-term." If you mean 5 years, true. If you mean 10+ years, false. The claim is technically accurate but the ambiguity is doing rhetorical work.

"Millions of patients have used semaglutide safely." True. Post-market surveillance covers 20+ million patient-years. But "safely" is a relative term. Adverse events occur in a minority of patients, but they occur. The claim is accurate but incomplete.

The most honest framing: "Semaglutide has been studied in controlled trials for 16 years, with the longest individual patient follow-up at 5.3 years. Post-market surveillance covers 9 years and 20+ million patient-years of real-world exposure. The evidence base is mature for 5-year safety and efficacy, but still accumulating for 10+ year outcomes."

That's a mouthful, which is why marketing simplifies it. But the nuance matters for informed decision-making.

FAQ

How long has Ozempic been studied? Ozempic (semaglutide) has been studied in clinical trials since 2008, with FDA approval in 2017 after 9 years of development. The phase 3 SUSTAIN trial program ran from 2015 to 2019. The longest published follow-up data for individual patients is 5.3 years from SUSTAIN-6 extension studies.

Is Ozempic a new medication? Ozempic was approved in 2017, making it 9 years old as of 2026. It's newer than earlier GLP-1 agonists like exenatide (2005) and liraglutide (2010), but it's part of a medication class that has been used in humans since 2005. The GLP-1 receptor pathway has been studied since 1992.

How long have GLP-1 medications been around? The first GLP-1 receptor agonist, exenatide (Byetta), was FDA-approved in 2005. As of 2026, GLP-1 medications have been prescribed for 21 years. The class now includes exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide (which is a dual GLP-1/GIP agonist).

What is the longest study of Ozempic? The SELECT cardiovascular outcomes trial is the longest published semaglutide study, with a median follow-up of 3.3 years (range 1.5 to 4.2 years) in 17,604 patients. Extension studies of the SUSTAIN-6 trial have followed individual patients for up to 5.3 years, but these results are published in smaller cohorts.

Has Ozempic been tested for long-term safety? Yes. Controlled trial data extends to 5.3 years, and post-market surveillance covers 9 years of real-world use in millions of patients. The evidence base is mature for 5-year safety but still accumulating for 10+ year outcomes. No late-emerging safety signals have appeared in the 5-year window.

How many people have been in Ozempic studies? More than 25,000 patients have been enrolled in semaglutide clinical trials across the SUSTAIN, STEP, SELECT, and other programs. The largest single trial was SELECT with 17,604 patients. Post-market real-world data covers more than 20 million patient-years of exposure worldwide.

When was semaglutide first tested in humans? The first human trials of semaglutide began in 2008 with Phase 1 pharmacokinetic studies. Phase 2 dose-ranging trials ran from 2012 to 2014. The phase 3 Phase 3 SUSTAIN program started enrolling patients in 2015.

Is compounded semaglutide as well-studied as Ozempic? No. The clinical trials studied Novo Nordisk's specific formulation, not compounded versions. Compounded semaglutide uses the same active ingredient (semaglutide), so the mechanism of action and receptor pharmacology are identical, but no head-to-head studies have compared bioavailability, stability, or outcomes between compounded and brand-name formulations.

What don't we know about Ozempic's long-term effects? We don't have controlled trial data beyond 5.3 years. Key unknowns include cancer risk with 10+ years of exposure, cognitive effects over decades, bone density effects with very long-term use, and optimal treatment duration for obesity. These knowledge gaps are normal for a medication 9 years post-approval and are being addressed by ongoing studies.

How does Ozempic's research compare to metformin? Metformin has 31 years of human use (FDA-approved 1995) and over 1 billion patient-years of exposure, far more than semaglutide's 9 years and 20 million patient-years. However, semaglutide has more rigorous cardiovascular outcomes data from the SELECT trial (17,604 patients, 3.3 years) than metformin, which has never had a dedicated cardiovascular outcomes trial of that size.

Are there ongoing studies of Ozempic? Yes. Major ongoing trials include FLOW (kidney outcomes in diabetic kidney disease, 3,533 patients, results expected late 2026), SOUL (cardiovascular outcomes with oral semaglutide, 12,000 patients, expected 2027), STEP HFpEF (heart failure outcomes, 731 patients), and OASIS-1 (Alzheimer's disease, 1,840 patients, expected 2025).

When will we have 10-year data on Ozempic? The first patients enrolled in SUSTAIN-6 in 2015 will reach 10 years of potential follow-up in 2025. Extension studies are ongoing, but publication typically lags data collection by 1-2 years. Expect the first 10-year controlled data to be published around 2026-2027, though it will be from small extension cohorts rather than the full trial population.

Sources

1. Thorens B et al. Cloning and functional expression of the human islet GLP-1 receptor. Diabetes. 1992.
2. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
3. Nauck MA et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 7): 32 weeks of treatment in patients with type 2 diabetes taking metformin. Diabetes Care. 2016.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
6. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023.
7. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
9. Pasternak B et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. BMJ. 2024.
10. Marso SP et al. Effects of semaglutide on cardiovascular outcomes in type 2 diabetes: 4-year follow-up of SUSTAIN-6. Circulation. 2022.
11. Aroda VR et al. Long-term efficacy and safety of semaglutide in patients with type 2 diabetes: SUSTAIN 5 extension. Diabetes Obesity and Metabolism. 2021.
12. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022.
13. Weghuber D et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). New England Journal of Medicine. 2022.
14. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Byetta is a registered trademark of AstraZeneca. Victoza and Saxenda are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How long has Ozempic been studied?", "acceptedAnswer": { "@type": "Answer", "text": "Ozempic (semaglutide) has been studied in clinical trials since 2008, with FDA approval in 2017 after 9 years of development. The phase 3 SUSTAIN trial program ran from 2015 to 2019. The longest published follow-up data for individual patients is 5.3 years from SUSTAIN-6 extension studies." } }, { "@type": "Question", "name": "Is Ozempic a new medication?", "acceptedAnswer": { "@type": "Answer", "text": "Ozempic was approved in 2017, making it 9 years old as of 2026. It's newer than earlier GLP-1 agonists like exenatide (2005) and liraglutide (2010), but it's part of a medication class that has been used in humans since 2005. The GLP-1 receptor pathway has been studied since 1992." } }, { "@type": "Question", "name": "How long have GLP-1 medications been around?", "acceptedAnswer": { "@type": "Answer", "text": "The first GLP-1 receptor agonist, exenatide (Byetta), was FDA-approved in 2005. As of 2026, GLP-1 medications have been prescribed for 21 years. The class now includes exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide." } }, { "@type": "Question", "name": "What is the longest study of Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "The SELECT cardiovascular outcomes trial is the longest published semaglutide study, with a median follow-up of 3.3 years in 17,604 patients. Extension studies of the SUSTAIN-6 trial have followed individual patients for up to 5.3 years." } }, { "@type": "Question", "name": "Has Ozempic been tested for long-term safety?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Controlled trial data extends to 5.3 years, and post-market surveillance covers 9 years of real-world use in millions of patients. The evidence base is mature for 5-year safety but still accumulating for 10+ year outcomes." } }, { "@type": "Question", "name": "How many people have been in Ozempic studies?", "acceptedAnswer": { "@type": "Answer", "text": "More than 25,000 patients have been enrolled in semaglutide clinical trials. The largest single trial was SELECT with 17,604 patients. Post-market real-world data covers more than 20 million patient-years of exposure worldwide." } }, { "@type": "Question", "name": "When was semaglutide first tested in humans?", "acceptedAnswer": { "@type": "Answer", "text": "The first human trials of semaglutide began in 2008 with Phase 1 pharmacokinetic studies. Phase 2 dose-ranging trials ran from 2012 to 2014. The phase 3 Phase 3 SUSTAIN program started enrolling patients in 2015." } }, { "@type": "Question", "name": "Is compounded semaglutide as well-studied as Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "No. The clinical trials studied Novo Nordisk's specific formulation. Compounded semaglutide uses the same active ingredient, so the mechanism of action is identical, but no head-to